Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
26 April 2018

 Description: 2018 Macah new Tags: Paediatrics, mother and child, healthcare, community, research, academic hospital, Free State.   

Rolene Strauss Patron of the MACAH Foundation, Oupa Mohoje,
Cheetahs rugby union player, and Kesa Molotsane
who are both champions of the MACAH Foundation.
Photo: Johan Roux

Description: 2018 new new MACAH Tags: Paediatrics, mother and child, healthcare, community, research, academic hospital, Free State.

From left is: Prof Gert van Zyl, MACAH Foundation’s founding
Director and Chairman; Khumo Selebano,
newly appointed Director; Dr Riana van Zyl founding director,
and Prof Andre Venter, Founding director and Project Leader.
Photo: Johan Roux



The Mother and Child Academic Hospital (Macah) Foundation was launched at the University of the Free State (UFS) on 24 April 2018. The foundation is instrumental in the building of a state-of-the-art academic hospital that will provide antenatal care and comprehensive health services for mothers, infants and children in Central South Africa. The hospital will be developed under a project in a partnership between UFS, Afrisky Holdings, and the Free State Department of Health, and will be located on the university’s Bloemfontein Campus but will be privately owned and operated.  

Prof Francis Petersen, UFS Rector and Vice-Chancellor, said in his opening remarks this high-level partnership was a demonstration of the power of working together to implement innovation and development, promoting research and academic excellence, while serving communities that are most in need. “This project is possibly the first of its kind in South Africa. I am really proud that the UFS can be a part of it,” he said. 

Officials from the Mangaung Metropolitan Municipality;  Deputy Director General of the Free State Department of Health, Mr Sekgothe Polelo; members of the UFS rectorate; senior academics in the Faculty of Health Sciences; Dr Rolene Strauss, former Miss World and patron of the Macah Foundation; as well Kesa Molotsane, athlete and UFS student, who is the new face of the Macah Foundation, as well as Oupa Mohoje, Springbok rugby player and captain of the Toyota Free State Cheetahs, who is also the face Macah Foundation among others, were present at the event. Prof Gert van Zyl, Dean of the Faculty of Health Sciences, said the university had a pivotal role to play in shaping the future of children who are the future generation. “If we fail our children, we fail our future, our culture and our being,” he said.

The Macah Foundation’s “Make the first 1000 Days Count” programme emphasises the importance of childcare in the first 1000 days. By the age of five, almost 90% of a child’s brain will be developed. Therefore, it is vital that this period is well monitored to ensure the child grows to be a vigorous and happy individual. As nurturer, a mother’s health is just as significant from conception to birth and beyond. The R20-million programme is still in its early stages, but has already received great support.

Prof André Venter, one of the founding directors of Macah, and Head of Paediatrics and Child Health at the UFS Faculty of Health Sciences, said the success of the mother and child hospital was like a dream come true. 

“We have been working on this concept for seven years. It is a privilege for me to work with children, but more so when we can combine so many skills and expertise in developing a world-class facility that will help members of our communities to thrive.”

The foundation is growing steadily and its founding directors are calling on corporates, businesses, and individuals to support it through their influence, loyalty and financial means.

To find out more about the foundation and pledge your support, visit www.macahfoundation.org.za or send an email to Tertia de Bruin on debruintr@ufs.ac.za or  foundation@macahfoundation.org.za

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept